Time filter

Source Type

Lanoy E.,French Institute of Health and Medical Research | Lanoy E.,University Pierre and Marie Curie | Rosenberg P.S.,U.S. National Cancer Institute | Fily F.,Center Hospitalier University Pontchaillou | And 10 more authors.
Blood | Year: 2011

Hodgkin lymphoma (HL) incidence with HIV infection may have increased with the introduction of combination antiretroviral therapy (cART), suggesting that immune reconstitution may contribute to some cases. We evaluated HL risk with cART during the first months of treatment. With 187 HL cases among 64 368 HIV patients in France, relative rates (RRs) and 95% confidence intervals (CIs) of HL were estimated using Poisson models for duration of cART, CD4 count, and HIV load, with and without adjustment for demographic/ clinical covariates. HL risk was unrelated to cART use overall, but it was related to time intervals after cART initiation (P = .006). Risk was especially and significantly elevated in months 1-3 on cART (RR 2.95, CI 1.64-5.31), lower in months 4-6 (RR 1.63), and null with longer use (RR 1.00). CD4 count was strongly associated with HL risk (P < 10-6), with the highest HL incidence at 50-99 CD4 cells/mm3. With adjustment for CD4 count and covariates, HL risk was elevated, but not significantly (RR 1.42), in months 1-3 on cART. HIV load had no added effect. HL risk increased significantly soon after cART initiation, which was largely explained by the CD4 count. Further studies of HIV-associated HL are needed. © 2011 by The American Society of Hematology.


Mahe G.,French Institute of Health and Medical Research | Ronziere T.,Center Hospitalier University Pontchaillou | Laviolle B.,Rennes University Hospital Center | Golfier V.,Center Hospitalier Of Saint Brieuc | And 3 more authors.
Journal of Vascular Surgery | Year: 2010

Objective: Ischemic strokes represent more than 80% of total strokes in Western countries. The influence of dietary factors on ischemic stroke risk is debated mainly because available data are limited. Our objective was to compare the dietary pattern of symptomatic ischemic stroke patients under 65 years old with control subjects using a validated 14-item food frequency questionnaire (FFQ). We also compared symptomatic ischemic stroke patients with carotid atherosclerosis with those without according to the presence or the absence of carotid plaque defined by duplex scanning. Methods: This was a case-control multi-center study that took place in one University hospital and two general hospitals in France. One hundred twenty-four symptomatic ischemic stroke patients (confirmation by a neurologist and imaging; 66% smokers) and 50 controls (34% smokers) without any known cardiovascular disease or previous nutritional advice were included. The main outcome measure(s) were intake scores for saturated (SFA), monounsaturated (MUFA), Ω-3 polyunsaturated (Ω-3 PUFA), and Ω-6 polyunsaturated fatty acids (Ω-6PUFA). Fruit and vegetables and an overall cardiovascular dietary score were evaluated with the FFQ. The overall cardiovascular score is calculated as (MUFA + Ω-3 PUFA + fruits and vegetables) - (SFA) scores. Results: Compared with controls, ischemic stroke patients had a higher SFA score (6.6 ± 3.0 vs 4.9 ± 2.7; P < .001), lower scores of MUFA (0.8 ± 0.9 vs 1.5 ± 1.2; P < .001), Ω-3 PUFA (1.7 ± 1.6 vs 2.2 ± 1.5; P = .013), Ω-6PUFA (2.6 ± 2.5 vs 3.9 ± 2.7; P = .002), fruit and vegetables (2.9 ± 1.7 vs 3.8 ± 1.6; P = .005), and a lower overall dietary score (-1.2 ± 5.0 vs 2.5 ± 4.4; P < .001). These results remained statistically significant after adjustment for age, gender, and smoking status. Ischemic stroke patients with carotid atherosclerosis (n = 54) had a worse overall cardiovascular dietary score than those without (n = 68): -2.2 ± 4.4 vs -0.2 ± 5.2; P = .024. Conclusion: Compared with controls, ischemic stroke patients, especially those with carotid atherosclerosis, have an unfavorable dietary pattern (high SFA, low fruit and vegetables, and Ω-3 PUFA consumptions) that may have been a facilitating condition of the ischemic stroke. Dietary recommendations of a healthy diet should be useful in ischemic stroke prevention, especially in patients with cardiovascular risk factors. © 2010 Society for Vascular Surgery.


Patent
French National Center for Scientific Research, Center Hospitalier University Pontchaillou and University of Rennes 1 | Date: 2011-03-04

The invention relates to a mixture comprising protolichesterinic acid or a salt thereof or a diastereoisomer thereof or a derivative thereof, and lichesterinic acid or a salt thereof or an enantiomer thereof or a derivative thereof, for use for stimulating pigmentation of the skin and/or of its appendages. The invention also relates to derivatives of lichesterinic acid of formula (A).


Patent
University of Rennes 1, French National Center for Scientific Research and Center Hospitalier University Pontchaillou | Date: 2014-11-06

The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients survival irrespective of the treatment administered.


Patent
French National Center for Scientific Research, University of Rennes 1 and Center Hospitalier University Pontchaillou | Date: 2013-04-18

The invention relates to the cosmetic use of a compound chosen from the compounds of formula (A) and the salts of same as an agent for depigmenting the skin and/or keratinous appendages.


Hsing J.M.,Beth Israel Deaconess Medical Center | Selzman K.A.,University of Utah | Leclercq C.,Center Hospitalier University Pontchaillou | Pires L.A.,St John Hospital and Medical Center | And 4 more authors.
Circulation: Arrhythmia and Electrophysiology | Year: 2011

Background-For patients with symptomatic New York Heart Association class III or IV, ejection fraction ≤35%, and QRS ≥130 ms, cardiac resynchronization therapy (CRT) has become an established treatment option. However, use of these implant criteria fails to result in clinical or echocardiographic improvement in 30% to 45% of CRT patients. Methods and Results-The Predictors of Response to CRT (PROSPECT)-ECG is a substudy of the prospective observational PROSPECT trial. ECGs collected before, during, and after CRT implantation were analyzed. Primary outcomes were improvement in clinical composite score (CCS) and reduction of left ventricular end systolic volume (LVESV) of >15% after 6 months. Age, sex, cause of cardiomyopathy, myocardial infarction location, right ventricular function, mitral regurgitation, preimplantation QRS width, preimplantation PR interval, preimplantation right ventricular-paced QRS width, preimplantation axis categories, LV-paced QRS width, postimplantation axis categories, difference between biventricular (Bi-V) pacing and preimplantation QRS width, and QRS bundle branch morphological features were analyzed univariably in logistic regression models to predict outcomes. All significant predictors (α=0.1), age, and sex were used for multivariable analyses. Cardiomyopathy cause interaction and subanalyses were also performed. In multivariable analyses, only QRS left bundle branch morphological features predicted both CCS (odds ratio [OR]=2.46, P=0.02) and LVESV (OR=2.89, P=0.048) response. The difference between Bi-V and preimplantation QRS width predicted CCS improvement (OR=0.89, P=0.04). LV-paced QRS width predicted LVESV reduction (OR=0.86, P=0.01). Specifically, an LV-paced QRS width of ≤200 ms was predictive of nonischemic LVESV reduction (OR=5.12, P=0.01). Conclusions-Baseline left bundle branch QRS morphological features, LV-paced QRS width, and the difference between Bi-V and preimplantation QRS width can predict positive outcomes after CRT and may represent a novel intraprocedural method to optimize coronary sinus lead placement. © 2011 American Heart Association, Inc.


Ribrag V.,Institute Gustave Roussy | Dupuis J.,Center Hospitalier University Henri Mondor Chenevier | Tilly H.,Center Henri Becquerel | Morschhauser F.,Lille University of Science and Technology | And 11 more authors.
Clinical Cancer Research | Year: 2014

Purpose: To determine recommended dose, dose-limiting toxicity, safety profile, pharmacokinetics, preliminary antitumor activity, and exploratory pharmacodynamics of SAR3419, an antibody-drug conjugate targeting CD19, administered alone by intravenous infusion weekly (qw), in a dose-escalation phase I study in patients with refractory/relapsed (R/R) non-Hodgkin lymphoma (NHL). Experimental Design: Patients with R/R CD19+ B-NHL were treated with escalating doses of SAR3419 repeated qw for eight to 12 doses. On the basis of clinical evidence of late or cumulative toxicities, the study protocol was amended to test an "optimized" administration schedule consisting of four qw doses followed by four biweekly (q2w) doses (qw/q2w) at the recommended dose with the intent of reducing drug accumulation. Results: Forty-four patients were treated on seven dose levels ranging from 5 to 70 mg/m2. SAR3419 recommended dose was determined as 55 mg/m2 qw. Twenty-five patients received the qw/q2w schedule at 55 mg/m2, which showed an improved safety profile compared with the qw schedule. Antilymphoma activity was observed with both schedules in around 30% of patients with either indolent or aggressive diseases. SAR3419 displayed a long terminal half-life (approximately 7 days) and a low clearance (approximately 0.6 L/d), with no dose effect. The qw/q2w schedule allowed limiting accumulation with a decrease in SAR3419 plasma trough and average concentrations by around 1.4-fold compared with the qw schedule. Conclusion: While administered weekly, SAR3419 is well tolerated and active. The qw/q2w schedule that shows an improved safety profile and preserves antilymphoma activity is selected for clinical phase II studies. Clin Cancer Res; 20(1); 213-20. © 2013 AACR.


Droitcourt C.,Center Hospitalier University Pontchaillou
Revue Francophone des Laboratoires | Year: 2013

Summary Identifying the etiology of alopecia is a multi-staged process including medical history, physical examination and dermoscopy, in order to classify alopecia: localized or diffuse; cicatricial or not cicatricial; genetic or not. This classification has some limits: several hair-loss disorders can have different clinical aspects. The most frequent clinical situation for mycologist is localized squamous alopecia in which differential diagnosis of ringworm must be considered including psoriasis, pityriasis amiantacea, cutaneous lymphoma and lupus. In some particular clinical presentations, histological or infectious skin specimens may provide valuable information regarding their etiology. © 2013 - Elsevier Masson SAS - Tous droits réservés.


The SEP-Bretagne network draws on the skills of the health professionals involved with patients with Multiple sclerosis. It brings together medical and paramedical professionals, to support actions aimed at improving the care pathway and the quality of life of patients. © 2015 Elsevier Masson SAS. All rights reserved.


Patent
Center Hospitalier University Pontchaillou | Date: 2011-12-13

The present invention relates to gene promoters whose methylation status correlates with the clinical survival outcome of glioblastoma patients treated according to the Stupp protocol. More specifically, the invention provides methods and kits for the prognosis of survival outcome and/or treatment response in glioblastoma patients.

Loading Center Hospitalier University Pontchaillou collaborators
Loading Center Hospitalier University Pontchaillou collaborators